Regeneron to invest additional $ 350 mn in Irish biologics plant

 
Leonard Schleifer, president and chief executive officer of Regeneron, said, “With a growing portfolio of marketed medicines and an innovative pipeline rooted in cutting-edge science and technology, Regeneron is one of the fastest-growing global biopharmaceutical companies. The Limerick facility will play an essential role in ensuring Regeneron delivers on our mission to consistently and repeatedly bring new medicines to patients with serious diseases.”
 
Regeneron's 400,000 sq ft biologics production facility in Limerick is now operational with the first production line on track to enter validation before year end 2015. When complete, Regeneron’s Raheen Park facility will be the largest-scale bulk biologics active pharmaceutical ingredient (API) production facility in Ireland. IOPS is responsible for the production, packaging, labelling and delivery of Regeneron products. IOPS manufactures a broad range of biopharmaceuticals for patients worldwide, including therapeutic proteins approved for marketing by regional or national regulatory agencies and those involved in clinical studies.

 
In addition to IOPS' significant operations in Limerick, Regeneron also has a growing multi-functional team in Dublin supporting its business in Europe.